Cilcare's CIL001 Targets Cochlear Synaptopathy — An American/French Collaboration

'Cilcare expands its collaboration network to accelerate revolutionary treatment for cochlear synaptopathy with new clinical trial and biomarker innovation'

CIL001 is focusing on cochlear 'synaptopathy' — oh dear. Bad memories.

Cilcare's main website lists four products.

People may want to dig in to find out more...

 

Excerpt from a recent article on the New Scientist:

 

@Fields, that's a good find, along with Rinri Therapeutics, which uses stem cells to proliferate into auditory nerve cells. This is, though, distinct from synapses.

 

Imagine we could take a pill and repair these nerves!

 

I personally thought this was a little funny:

Imagine going from hearing loss and tinnitus on one end of the scale to not being able to sleep because of the crying baby three doors down the street on the other.

UNLIMITED SYNAPSES!

 

I'd take it even if it was a suppository!

 

You don't have to imagine if you have hyperacusis, lol.

 

Superior hearing would be like higher frequency range... it could create issues with some stuff. I'd gladly take this over tinnitus and fragile ears.

Suppository would be so awesome! Like, hey my hearing turn to shit... but now we can use the asshole to fix it.

 

Hopefully, increased hearing would turn down the brain's central gain and reduce hyperacusis.

My tinnitus sucks, but my hyperacusis is horrible.

 

It looks like Cilcare licensed Paliroden and Xaliproden.

→ 4-phenyl-tetrahydropyridine derivatives for treating hearing diseases

 

I did reach out to Cilcare about clinical trials for tinnitus. They did not provide much new information, but here is their response:

If you live in any of these areas, it may not be a bad idea to contact them and get your name on file for any clinical trials.

 

Treating cochlear synaptopathy wouldn't make sounds any louder. Just clearer.

 

That reminds me somewhat of the "speech-in-noise test" that the ENT researchers use. Or maybe I'm on the wrong track.

FYI, I use two things for sleeping, etc.: an ordinary FM radio with a mellow sound and a sound machine that can play water trickling, waves, wind, rain, a fan, and white noise. In the early morning, when I turn on the news, turning off the sound machine makes things clearer. So, I have mild optimism that they may be onto something that helps somewhat.

 

Back in June, Cilcare and Shionogi announced an exclusive Option Agreement for innovative hearing disorder treatment. Under the terms of the agreement:

• Shionogi will receive an exclusive option to license global rights to CIL001 and/or CIL003.
• Cilcare will receive an upfront payment of €15 million.
• Cilcare is eligible to receive up to €400 million in milestone payments upon successful development and commercialization of the drug candidates.
• Shionogi will decide whether to exercise the option right based on the results of the Phase 2a studies of CIL001 and preclinical study data of CIL003, both to be conducted by Cilcare.

→ Cilcare and Shionogi announce exclusive Option Agreement for innovative hearing disorder treatment

 

Does anyone know how Cilcare's CIL001 differs from Otonomy's research? It seems to be the same molecule that Otonomy tested.

 

Completely different, it seems. Xaliproden here vs. BDNF for Otonomy.

 

I think this is one of the most promising treatments for tinnitus caused by hearing loss or acoustic trauma. It's also nice to see that tinnitus is their key focus compared to these other restorative approaches.

 

This is a 5-HT1A agonist.

 

It remains to be seen, but I am glad they are trying.

It seems that this is supposed to increase BDNF production.

 

Thank you for sharing. I will give it a shot. As someone from the Netherlands, I might be able to participate.

 

I forgot to mention it in my previous post, but Cilcare was also awarded €4.2 million by the French government.

It'll be interesting to see where specifically they'll set up shop for their clinical trials in 2025 (if all goes well). Depending on the distance and format, I might try to apply.

 

Correct me here; my memory is not 100% (and never was). But I seem to recall noting that Otonomy was a pan-European conglomerate of researchers. They were experimenting with their molecule at the same time as Frequency Therapeutics was stealing the show in a wave of optimism -- some might say a wave of exuberance. And then (or maybe because of this), Otonomy threw in the towel, saying they had found nothing. Correct me if I've got it wrong.

 

You got it completely wrong.

Otonomy was also 100% US-based, and their clinical trials failed multiple times, after which they were forced to throw in the towel. They did no such thing because of Frequency Therapeutics.

 

Otonomy was USA-based but sponsored some European clinical trial sites for the Phase 2 OTO-313 trial. Sheffield University was one of those sites.

 

This is the one you're thinking of.

 

Spot on! It went under the name of Regain... or, in the link above, Regain Consortium.